CRC 2000: all centres/groups, trials/strata and treatments

Key: Green - ineligible for overview, nonstandard randomisation or otherwise excluded; Blue - data not (yet) received

11 Southampton and Liverpool, U.K. {Taylor: JUL-1992 (UPDATED SIX TIMES)}

1101 75A Portal Vein Infusion: Entry SEP-1975 to APR-1984 (281 patients were entered; 1 possibly missing)

1 Control
2 5-Fluoro-Uracil intraportal perfusion

1102 81D Antibiotic Trial: Entry 1981 to 1982; {AB} (? patients were entered; not received)

1 Cefoxitin
2 Gentamicin + Metronidazole

12 Virginia Mason, U.S.A. {Crowley, Ryan: FEB-1991}

1201 81A Colo-Rectal Study: Portal vein infusion: Entry 1981 to 1987 (301 patients were entered; dates unknown)

1 Control
2 Heparin intraportal
3 (Heparin + Mitomycin-C + 5-Fluoro-Uracil) intraportal

13 Swiss Group for Clinical Cancer Research (S.A.K.K.) {Castiglione, Herrmann, Laffer, Maibach, Metzger, Pampallona, Sandro: JAN-1993 (REVISED VERSION (UPDATED TWICE))}

1301 81B S.A.K.K. 40/81: Entry JUL-1981 to JUN-1987 (533 patients were entered)

1 Control
2 (Mitomycin-C + 5-Fluoro-Uracil) intraportal

1302 87A S.A.K.K. 40/87: Entry 1987 to 1992 (?750 patients were entered; synthetic data only, no event)

1 (5-Fluoro-Uracil + Mitomycin-C) intraportal
2 (5-Fluoro-Uracil + Mitomycin-C) (perioperative, central venous catheter)
3 Control

1303 S.A.K.K. 40/93 (Herrmann, Laffer): Radical Resection; pT1-4 pN>0 M0 (Dukes B2), pT3-4 pN0 M0 (Dukes C); Colon Cancer; Entry ? (? patients were entered; not received)

1 (5-Fluoro-Uracil + Mitomycin-C) intraportal/iv then 5-Fluoro-Uracil [450mg/m² iv] q1wk x 1yr + Levamisole x 1yr
2 (5-Fluoro-Uracil + Mitomycin-C) intraportal/iv then 5-Fluoro-Uracil [600mg/m² iv] q1wk x 1yr
3 (5-Fluoro-Uracil + Mitomycin-C) intraportal/iv

14 Rotterdam, Netherlands {van Assendelft, Boulis-Wassif, van Putten, Treurniet-Donker, Wereldsma, Wiggers: SEP-1993 (THIRD REVISED VERSION)}

1401 81C CRAC I: Entry JUL-1981 to AUG-1984 (318 patients were entered)

1 (5-Fluoro-Uracil + Heparin) intraportal
2 Urokinase intraportal
3 Control

1402 72A Radiotherapy Trial: Rectal Cancer; Entry 1972 to 1976 (100 patients were entered; data permanently lost: synthetic data only, no recurrence information)

1 Radiotherapy preoperative
2 Control

1403 79A Surgery Trial: Colon Cancer; Entry JAN-1979 to FEB-1982 (304 patients were entered; 68 patients possibly missing)

1 'No-Touch Isolation' Technique
2 Conventional Resection Technique

1404 81U CRAC II: Rectal Cancer; Dukes B2, C1, C2; Entry JUL-1981 to OCT-1988 (172 patients were entered)

1 Radiotherapy [50Gy postoperative]
2 Control

15 St Mary's Hospital, London, U.K. {Fry, Hittinger: MAY-1993 (REVISED VERSION, UPDATED THREE TIMES)}

1501 80A LBC Trial: Post-Laparotomy Randomisation; Entry MAY-1980 to AUG-1983 (457 patients were entered)

1 Control
2 Heparin intraportal
3 (Heparin + 5-Fluoro-Uracil) intraportal

16 Belfast City Hospital, U.K. {Diamond: 1992}

1601 Antibiotic Trial: Entry ?? {AB} (? patients were entered; not received)

1 Mezlocillin
2 Cefuroxime + Metronidazole

17 Birmingham General Hospital, U.K. {Dykes, Keighley: 1992}

1701 Antibiotic Trial: Advanced Disease; Entry ?? {AB} (? patients were entered; not received)

1 Cefoxitin
2 Gentamicin + Metronidazole

1702 __A1 Bowel Preparation Trial: Advanced Disease; Entry ?? {AB} (? patients were entered; not received)

1 Mannitol (po)
2 'X Prep' (sennosides A & B)

1703 __A2 Antibiotic Trial: Advanced Disease; Patients from trial 1702; Entry ?? {AB} (? patients were entered; not received)

1 Metronidazole
2 Metronidazole + Gentamicin

1704 Antibiotic Trial: Advanced Disease; Entry ?? {AB} (? patients were entered; not received)

1 Control
2 Metronidazole + Neomycin

1705 Antibiotic Trial: Advanced Disease; Entry ?? {AB} (? patients were entered; not received)

1 Control
2 Lincomycin

1706 Antibiotic Trial: Advanced Disease; Entry ?? {AB} (? patients were entered; not received)

1 Metronidazole + Mezlocillin
2 Metronidazole + Cefuroxime

1707 Antibiotic Trial: Advanced Disease; Entry ?? {AB} (? patients were entered; not received)

1 Metronidazole + Ceftriaxone
2 Metronidazole + Gentamicin

1708 Antibiotic Trial: Advanced Disease; Entry ?? {AB} (? patients were entered; not received)

1 Neomycin + Erythromycin
2 Metronidazole + Ceftriaxone

1709 Antibiotic Trial: Advanced Disease; Entry ?? {AB} (? patients were entered; not received)

1 Metronidazole + Kanamycin (po)
2 Metronidazole + Kanamycin (systemic)

1710 Cytocidal Washout Trial: Advanced Disease; Entry ?? {AB} (? patients were entered; not received)

1 Control
2 Colonic Irrigation (rectal and proximal)

1711 Follow-Up Trial: Advanced Disease; Entry ?? (? patients were entered; not received)

1 Control
2 Chemotherapy after CEA follow-up

18 Bristol Royal Infirmary, U.K. {Griffiths: 1992}

1801 Antibiotic Trial: Entry ?? {AB} (? patients were entered; not received)

1 Control
2 Lincomycin + Tobramycin

19 Cancer Research Campaign, U.K. {Allen-Marsh: 1992}

1901 82C CRC CEA Trial: Entry 1982 to ?? (? patients were entered; not received)

1 Normal follow-up
2 CEA investigation with further surgery if necessary

1902 87B CRC FUDR Trial: Liver Metastases; Entry 1987 to ?? (? patients were entered; not received)

1 Control
2 5-Fluorodeoxyuridine (intrahepatic)

20 Cardiff, Wales {Everett: 1992}

2001 Antibiotic Trial: Entry ?? {AB} (? patients were entered; not received)

1 Control
2 Neomycin

21 Charing Cross Hospital, U.K. {Cann: 1992}

2101 Antibiotic Trial: Entry ?? {AB} (? patients were entered; not received)

1 Mezlocillin
2 Cefuroxime + Metronidazole

22 Royal Devon and Exeter Hospital, U.K. {Irvin: 1992}

2201 78Q Chemotherapy Trial: Entry 1978 to 1982 approx. (136 patients were entered; synthetic data only, no information about recurrence)

1 Control
2 5-Fluoro-Uracil

23 Edinburgh Royal Infirmary, Scotland {Dixon, Fearon: 1992}

2301 Antibiotic Trial (Dixon): Entry ?? {AB} (? patients were entered; not received)

1 Control
2 Cefamandole (pre-anaesthesia)
3 Cefamandole (post-anaesthesia)

2302 Supportive Care Trial (Fearon): Colonic Resection; Age 18-80; Entry ? Haematological Endpoints (20 patients were entered; not received)

1 Conventional Total Parenteral Nutrition
2 Glutamine-Containing Nutrition

24 Victoria Infirmary, Glasgow, Scotland {Gillespie: 1992}

2401 Antibiotic Trial: Entry ?? {AB} (? patients were entered; not received)

1 Control
2 Kanamycin + Metronidazole

25 Western Infirmary, Glasgow, Scotland {Bancewicz: 1992}

2501 77J Chemoimmunotherapy Trial: Entry 1977 (52 patients were entered; 20 patients possibly missing; data all destroyed: synthetic data only, no recurrence information)

1 Control
2 5-Fluoro-Uracil
3 5-Fluoro-Uracil + Levamisole

2502 85M Anastomosis Trial: Entry APR-1985 to APR-1989 (294 patients were entered; not received)

1 Sutured Anastomoses
2 Stapled Anastomoses

26 Hammersmith Hospital, London, U.K. {Galland, Sellwood: 1992}

2601 First Antibiotic Trial: Entry ?? {AB} (? patients were entered; not received)

1 Phthalylsulphathiazole
2 Bacitracin + Neomycin + Nystatin

2602 Second Antibiotic Trial: Entry ?? {AB} (? patients were entered; not received)

1 Phthalylsulphathiazole
2 Bacitracin + Neomycin + Nystatin

2603 Antibiotic Trial: Entry ?? {AB} (? patients were entered; not received)

1 Control
2 Lincomycin + Tobramycin
3 Povidone-Iodine

27 Hillingdon Hospital, Middlesex, U.K. {Stubbs: 1992}

2701 84A Antibiotic Trial: Entry 1984 to 1985 {AB} (? patients were entered; not received)

1 Mezlocillin
2 Cefuroxime + Metronidazole

28 Leeds General Infirmary, U.K. {Rosenberg: 1992}

2801 65A Antibiotic Trial: Entry 1965 to 1967 {AB} (? patients were entered; not received)

1 Control
2 Phthalylsulphathiazole
3 Phthalylsulphathiazole + Neomycin

29 Leicester, U.K. {Windle: 1992}

2901 80P Chemoimmunotherapy Trial: Entry 1980 to 1982 approx. (141 patients were entered; synthetic data only, no information about recurrence)

1 Control
2 5-Fluoro-Uracil
3 5-Fluoro-Uracil + Levamisole

30 Luton and Dunstable Hospital, U.K. {Fiddian: 1992}

3001 Antibiotic Trial: Entry ?? {AB} (? patients were entered; not received)

1 Gentamicin
2 Gentamicin + Metronidazole

31 Medical Research Council, U.K. {Duncan, Stenning: JUL-1996 (UPDATED TWICE)}

3101 75B MRC 1: Rectal Cancer; Entry JAN-1975 to AUG-1978 (850 patients were entered; 12 missing)

1 Control
2 Radiotherapy [5Gy, single dose] preoperative
3 Radiotherapy [20Gy, fractionated] preoperative

3102 81E MRC 2: Rectal Cancer; Entry NOV-1981 to OCT-1989 (279 patients were entered)

1 Control
2 Radiotherapy [40Gy] preoperative

3103 84B MRC 3: Rectal Cancer; Entry MAR-1984 to DEC-1989 (469 patients were entered)

1 Control
2 Radiotherapy [40Gy] postoperative

32 Withington Hospital, Manchester, U.K. {Carr: 1992}

3201 80B Antibiotic Trial: Entry 1980 to 1982 {AB} (? patients were entered; not received)

1 Metronidazole (preoperative)
2 Metronidazole (preoperative and 1 postoperative)
3 Metronidazole (preoperative and 2 postoperative)
4 Metronidazole (preoperative and 3 postoperative)

3202 82D Antibiotic Trial: Entry 1982 ff. {AB} (? patients were entered; not received)

1 Metronidazole
2 Metronidazole + Cefuroxime

33 Christie Hospital and Holt Radium Institute, Manchester, U.K. {Jones, Swindell: MAY-1996 (UPDATED TWICE)}

3301 82E North West Rectal Cancer Trial: Entry SEP-1982 to MAR-1987 (284 patients were entered)

1 Control
2 Radiotherapy [25Gy] preoperative

34 Trafford General Hospital, Manchester, U.K. {Kingston: 1992}

3401 84C Antibiotic Trial: Entry 1984 to 1987 {AB} (? patients were entered; not received)

1 Latamoxef
2 Cefuroxime + Metronidazole

36 Royal Victoria Infirmary, Newcastle, U.K. {Proud: 1992}

3601 Antibiotic Trial: Entry ?? {AB} (? patients were entered; not received)

1 Control
2 Metronidazole
3 Kanamycin + Metronidazole

37 Radcliffe Infirmary, Oxford, U.K. {Finch: 1992}

3701 77A Antibiotic Trial: Entry 1977 to 1978 {AB} (? patients were entered; not received)

1 Control
2 Cephradine (topical)
3 Cephradine (po)

38 John Radcliffe Hospital, Oxford, U.K. {Souter: 1992}

3801 75H Immunotherapy Trial: Entry NOV-1975 to JAN-1980 (92 patients were entered)

1 Cornybacterium Parvum
2 Control

39 Peterborough District Hospital, U.K. {Beggs: 1992}

3901 Antibiotic Trial: Entry ?? {AB} (? patients were entered; not received)

1 Neomycin (po) + Metronidazole (po)
2 Neomycin (po) + Metronidazole (iv)

40 Poole General Hospital, U.K. {Rowe-Jones: 1992}

4001 87C Antibiotic Trial: Entry 1987 to 1989 {AB} (? patients were entered; not received)

1 Cefotaxime + Metronidazole (preoperative)
2 Cefuroxime + Metronidazole (pre- and postoperative)

41 Rectal Cancer Group, St Mark's Hospital, London, U.K. {Goldberg, Nicholls, Northover, Nugent, Verne: JUN-1996 (UPDATED TWICE)}

4101 80C RCG 1: Rectal Cancer; Entry NOV-1980 to NOV-1984 (477 patients were entered)

1 Radiotherapy (preoperative)
2 Control

4102 Occult Blood Screening Trial (Verne): Compliance Endpoint; Age 40-74; Entry ? (1842 patients were entered; not received)

1 Early Detector
2 Coloscreen Self-Test
3 Haemoccult

4103 Sulindac Trial (Nugent): Advanced Familial Adenomatous Polyposis Patients; Polyposis and Mucosal Cell Endpoints; Entry ? (24 patients were entered; not received)

1 Sulindac
2 Control

42 Royal Free Hospital, London, U.K. {Higgins: 1992}

4201 Antibiotic Trial: Entry ?? {AB} (? patients were entered; not received)

1 Gentamicin + Lincomycin
2 Gentamicin + Metronidazole

4202 Antibiotic Trial: Entry ?? {AB} (? patients were entered; not received)

1 Co-trimoxazole + Metronidazole (perioperative)
2 Co-trimoxazole + Metronidazole (pre- and postoperative)

43 St Thomas' Hospital, London, U.K. {Eykyn: 1992}

4301 Antibiotic Trial: Entry ?? {AB} (? patients were entered; not received)

1 Control
2 Metronidazole

44 Scarborough Hospital, U.K. {Evans, Pollock, Sagar: 1992}

4401 Antibiotic Trial (Evans): Entry ?? {AB} (? patients were entered; not received)

1 Control
2 Cephaloridine

4402 Anastomosis Trial (Pollock): Entry ? (103 patients were entered; not received)

1 Sutured
2 Stapled

4403 Drainage Trial (Sagar): Colonic or Colorectal Resection; Entry ? (148 patients were entered; not received)

1 Control
2 Drain x 3d
3 Drain x 7d

45 Royal Shrewsbury Hospital, U.K. {Mitchell: 1992}

4501 Antibiotic Trial: Entry ?? {AB} (? patients were entered; not received)

1 Control
2 Cefuroxime
3 Cefuroxime + Metronidazole

4502 Antibiotic Trial: Entry ?? {AB} (? patients were entered; not received)

1 Metronidazole
2 Cefuroxime + Metronidazole

46 Wexham Park Hospital, Slough, U.K. {Evans, Gilbert, Hellmann, Peto: SEP-1993}

4601 76A1 Chemotherapy Trial: Stage A, B, C; Entry 1976 ff. (240 patients were entered; synthetic data only, no recurrence information)

1 Control
2 Razoxane

4602 76A2 Chemotherapy Trial: Stage D; Entry 1976 ff. (32 patients were entered; synthetic data only, no recurrence information; 'ineligible')

1 Control
2 Razoxane

47 U.K.C.C.C.R., U.K. {James: 1992}

4701 89A1 AXIS: Rectal Cancer; Entry 1989 ff. (224 patients were entered by JUN-1996; synthetic data only, no event; not received)

1 Control
2 5-Fluoro-Uracil (intraportal)
3 Radiotherapy preoperative
4 Radiotherapy preoperative + 5-Fluoro-Uracil (intraportal)

4702 89A2 AXIS: Rectal Cancer; Entry 1989 ff. (413 patients were entered by JUN-1996; synthetic data only, no event; not received)

1 Control
2 5-Fluoro-Uracil (intraportal)
3 Radiotherapy postoperative
4 Radiotherapy postoperative + 5-Fluoro-Uracil (intraportal)

4703 89A3 AXIS: Colon and Rectal Cancer; Entry 1989 ff. (2574 patients were entered by JUN-1996; synthetic data only, no event; not received)

1 Control
2 5-Fluoro-Uracil (intraportal)

4704 89A4 AXIS: Rectal Cancer; Entry 1989 ff. (30 patients were entered by JUN-1996; synthetic data only, no event; not received)

1 Control
2 Radiotherapy preoperative

4705 89A5 AXIS: Rectal Cancer; Entry 1989 ff. (64 patients were entered by JUN-1996; synthetic data only, no event; not received)

1 Control
2 Radiotherapy postoperative

48 Veterans' Administration Hospital, Boston, U.S.A. {Wapnick: 1992}

4801 75C Antibiotic Trial: Entry 1975 to 1977 {AB} (? patients were entered; not received)

1 Kanamycin
2 Kanamycin + Erythromycin

49 C.A.L.G.B., U.S.A. {Frei, Mayer: 1992}

4901 CLB-7785: Entry 1978 ff. (never activated)

1 Radiotherapy (preoperative to pelvis)
2 Radiotherapy (preoperative to pelvis) + Radiotherapy (perineum)
3 Control

50 Central Oncology Group, U.S.A. {Grage: SEP-1993}

5001 COG 7032: Liver Metastases; Entry 1971 to 1976 (? patients were entered; not received)

1 5-Fluoro-Uracil (iv)
2 5-Fluoro-Uracil (hepatic artery)

5002 71B COG 7041 (Curative Surgery): Entry JUL-1971 to OCT-1976 (222 patients were entered; 3 possible double entries)

1 Control
2 5-Fluoro-Uracil

51 City of Hope National Medical Center, Duarte, U.S.A. {Kemeny: 1992}

5101 Liver Metatastases I: Solitary Liver Metastases; Entry 1982 to 1986 (? patients were entered; not received)

1 Resection of Liver Metastases
2 Resection of Liver Metastases + 5-Fluorodeoxyuridine (intrahepatic)

5102 82F Liver Metatastases II: Multiple Liver Metastases; Entry 1982 to 1986 (? patients were entered; not received)

1 5-Fluorodeoxyuridine (intrahepatic)
2 Resection of Liver Metastases + 5-Fluorodeoxyuridine (intrahepatic)

52 U.S. Universities {Banschek, Dixon, Holden: 1992}

5201 57A1 Chemotherapy Trial: Entry 1957 to 1958 (693 patients were entered; synthetic data only, no recurrence information; contains 5202 pro temp.)

1 Control
2 Triethylenethiophosphoramide -

5202 57A2 Chemotherapy Trial: Entry 1958 to 1960 (? patients were entered; in 5201 pro temp.)

1 Control
2 Triethylenethiophosphoramide -

53 Duke University Medical Center, Durham, U.S.A. {Laszlo, Shingleton: 1992}

5301 NCI-D78-032-149: Entry 1978 to 1980 (probably never activated)

1 Methyl-Lomustine + 5-Fluoro-Uracil + Vincristine
2 Methyl-Lomustine + 5-Fluoro-Uracil + Vincristine + Levamisole

5302 NCI-D78-032-162: Entry 1978 to 1981 (probably never activated)

1 Radiotherapy (preoperative)
2 Radiotherapy (postoperative)

5303 NCI-D81-032-559: Entry 1981 to 1983 (probably never activated)

1 Control
2 Methyl-Lomustine + 5-Fluoro-Uracil
3 Methyl-Lomustine + 5-Fluoro-Uracil + Mitomycin-C

54 Eastern Coöperative Oncology Group, U.S.A. {Harrington, Hoover, Mansour, Ryan: SEP-1993 (REVISED VERSION)}

5401 90A EST-1290: Entry 1990 ff/. (? patients were entered; not received)

1 Autologous Tumour Vaccine
2 5-Fluoro-Uracil + Levamisole
3 Autologous Tumour Vaccine + 5-Fluoro-Uracil + Levamisole

5402 75J EST-2276: Entry OCT-1975 to AUG-1978 (866 patients were entered; no recurrence site information)

1 5-Fluoro-Uracil
2 5-Fluoro-Uracil + Methyl-Lomustine

5403 76C EST-4276: Rectal Cancer; Stage B2, C1, C3; Entry JUL-1976 to MAY-1983 (307 patients were entered; no recurrence site information)

1 Radiotherapy (postoperative)
2 5-Fluoro-Uracil + Methyl-Lomustine
3 Radiotherapy (postoperative) + 5-Fluoro-Uracil + Methyl-Lomustine

5404 84D EST-5283: Stage B2, B3, C; Entry 1984 ff. (412 patients were entered; 349 patients were entered by SEP-1993; synthetic data only, no recurrence information)

1 Control
2 BCG-Tice + Tumour Cells (autologous)

5405 71C EST-0470: Liver Metastases; Entry 1971 ff. (? patients were entered; not received)

1 5-Fluoro-Uracil (systemic)
2 5-Fluorodeoxyuridine (intra-arterial)

5406 EST-2288 (part of INT-0089 Intergroup Study): Entry ? (? patients were entered; not received)

1 5-Fluoro-Uracil + Folinic Acid [low dose]
2 5-Fluoro-Uracil + Folinic Acid [high dose]
3 5-Fluoro-Uracil + Folinic Acid [low dose] + Levamisole
4 5-Fluoro-Uracil + Levamisole

55 Emory University, Atlanta, U.S.A. {Stone: 1992}

5501 74A Antibiotic Trial: Entry 1974 to 1976 {AB} (? patients were entered; not received)

1 Control
2 Cefazolin (pre- and postoperative)
3 Cefazolin (peri- and postoperative)
4 Cefazolin (postoperative)

56 Cleveland Clinic, Fort Lauderdale, U.S.A. {Jagelman: 1992}

5601 Antibiotic Trial: Entry ?? {AB} (? patients were entered; not received)

1 Cefotetan
2 Cefoxitin

57 Gastrointestinal Tumor Study Group, U.S.A. {Kaplan, Lindblad, Weaver: AUG-1993 (UPDATED)}

5701 75D GITSG-6175: Colon Cancer; Dukes B, C; Entry JUL-1975 to JUL-1979 (621 patients were entered)

1 Control
2 5-Fluoro-Uracil + Methyl-Lomustine
3 MER
4 5-Fluoro-Uracil + Methyl-Lomustine + MER

5702 GITSG-6178: Colon Cancer; Entry 1979 to 1980 (never activated)

1 Control
2 5-Fluoro-Uracil (portal)

5703 79C GITSG-6179: Colon Cancer; Entry SEP-1979 to NOV-1985 (317 patients were entered)

1 Control
2 Radiotherapy (to liver) + 5-Fluoro-Uracil x 6m

5704 75E GITSG-7175: Rectal Cancer; Entry AUG-1975 to JAN-1980 (227 patients were entered)

1 Control
2 5-Fluoro-Uracil + Methyl-Lomustine
3 Radiotherapy (postoperative)
4 5-Fluoro-Uracil + Methyl-Lomustine + Radiotherapy (postoperative)

5705 81G GITSG-7180: Rectal Cancer; Entry MAR-1981 to OCT-1985 (209 patients were entered; 1 patient possibly missing)

1 5-Fluoro-Uracil [300mg/m² on d1-5, 375mg/m² on d36-40, escalating to 325mg/m² on d1-5] x 1yr + Methyl-Lomustine
2 5-Fluoro-Uracil [350mg/m² on d1-5, monthly, escalating to 500mg/m²] x 6m

58 Medical College of Georgia, Atlanta, U.S.A. {DiPiro: 1992}

5801 Antibiotic Trial: Entry ?? {AB} (? patients were entered; not received)

1 Cefmetazole
2 Cefoxitin

59 Hoosier Oncology Group, U.S.A. {Mantravadi, Miller: 1992}

5901 85A Radiotherapy Trial: Colon Cancer; Stage C; Entry 1985 to 1989 (43 patients were entered; no event; synthetic data only, no recurrence information)

1 ³²P Chromic Phosphate (postoperative, intra-arterial)
2 Control

60 Houston, Texas, U.S.A. {Campos: SEP-1993 (UPDATED)}

6001 76D Immunotherapy Trial: Colon Cancer; Stage C; Entry JUN-1976 to DEC-1977 (25 patients were entered)

1 Vincristine + Mitomycin-C + 5-Fluoro-Uracil + Lomustine
2 Vincristine + Mitomycin-C + 5-Fluoro-Uracil + Lomustine + BCG x 2yr

61 Illinois University, U.S.A. {Briele, Mrazek, Nichols: 1992}

6101 56A Chemotherapy Trial: Entry 1956 ff. (62 patients were entered; synthetic data only, no information about recurrence)

1 Control
2 Nitrogen Mustard

6102 Antibiotic Trial: Colon cancer; Entry ?? {AB} (? patients were entered; not received)

1 Control
2 Neomycin + Erythromycin

62 University Hospital, Jacksonville, U.S.A. {Shatney: 1992}

6201 Antibiotic Trial: Entry ?? {AB} (? patients were entered; not received)

1 Cefotaxime
2 Cefoxitin

63 Kansas University, U.S.A. {Leo: 1992}

6301 Antibiotic Trial: Colon Cancer; Entry ?? {AB} (? patients were entered; not received)

1 Neomycin + Erythromycin
2 Neomycin + Oxytetracycline

64 Maryland University, U.S.A. {Didolkar, Elias: 1992}

6401 Suturing Trial: Entry ?? (? patients were entered; not received)

1 Conventionally hand-sutured two-layer bowel anastomoses
2 Mechanically-stapled bowel anastomoses

6402 80D MD-CO-1: Age 20-80; Entry 1980 to 1980 (? patients were entered; not received)

1 5-Fluoro-Uracil
2 Tumour Cells (autologous)

6403 86A UMAB-VOL-0033: Age < 80; Entry 1986 to 1986 (possibly never activated)

1 Control
2 Tumour-Associated Antigen

6404 76S Autologous Tumour Extract Trial: Stage C; Entry 1976 ff. (possibly never activated)

1 Control
2 Autologous Tumour Extract

65 Massachusetts General Hospital, U.S.A. {Hanna, Hoover: AUG-1993 (UPDATED)}

6501 81H Immunotherapy Trial: Entry JAN-1981 to NOV-1988 (98 patients were entered)

1 Control
2 Autologous Tumour-Cell BCG Vaccine

6502 87D1 MGH-CR1: Age > 18; Entry 1987 ff. (? patients were entered; not received)

1 Control
2 Tumour Cells (autologous) + BCG-Tice
3 BCG-Tice + Cyclophosphamide

6503 87D2 MGH-CR3: Age > 18; Entry 1987 ff. (? patients were entered; not received)

1 5-Fluoro-Uracil
2 5-Fluoro-Uracil + Autologous Tumour-Cell BCG Vaccine
3 5-Fluoro-Uracil + BCG-Tice + Cyclophosphamide

6504 87D3 MGH-CR5: Age > 18; Patients may have had previous cancer or receieved prior radiotherapy or chemotherapy; Entry 1987 ff. (? patients were entered; not received)

1 Control
2 Tumour Cells (autologous) + BCG-Tice
3 BCG-Tice + Cyclophosphamide

6505 87D4 MGH-CR6: Age > 18; Entry 1987 ff. (? patients were entered; not received)

1 Control
2 Tumour Cells (autologous) + BCG-Tice
3 BCG-Tice + Cyclophosphamide

67 Miami University, U.S.A. {Polk: 1992}

6701 66A Antibiotic Trial: Entry 1966 to 1968 {AB} (? patients were entered; not received)

1 Control
2 Cephaloridine

68 M.D. Anderson Hospital and Tumor Institute, U.S.A. {Jessup, Mavligit: 1993}

6801 73A Chemotherapy Trial: Stage C; Entry 1973 to 1976 (120 patients were entered; 1 patient possibly missing; synthetic data only, no recurrence information)

1 BCG-Tice
2 BCG-Tice + 5-Fluoro-Uracil

6802 MDA-GS-8101: Entry 1981 to 1983 (approx. 70 patients were entered; not received; not randomised)

1 Control
2 Tumour Cells (irradiated) + BCG-Tice

6803 BCG Trial: Colon Cancer; Stage C; Entry 1973 to 1976 (approx. 82 patients were entered; probably mistaken for 6801)

1 5-Fluoro-Uracil
2 5-Fluoro-Uracil + BCG

69 Memorial Sloan Kettering Cancer Center, U.S.A. {Kemeny, Quan, Yagoda: 1992}

6901 Radiotherapy Trial: Rectal Cancer; Entry 1960 to 1967 (346 patients were entered (700 1957-1965 - Quan); date-of-birth allocations; not received)

1 Radiotherapy (preoperative)
2 Control

6902 77K Immunotherapy Trial: Rectal Cancer; Entry 1977 ff. (approx. 41 patients were entered; synthetic data only, no recurrence information, no event)

1 5-Fluoro-Uracil + Methyl-Lomustine
2 5-Fluoro-Uracil + Methyl-Lomustine + Corynebacterium Parvum

6903 82G MSKCC-8284: Age > 18; Liver Metastases; Entry 1982 to 1986 (? patients were entered; not received)

1 5-Fluorodeoxyuridine (intrahepatic)
2 5-Fluorodeoxyuridine (iv)

6904 83A MSKCC-8368: Rectal Cancer; Entry 1983 to 1987 (100 patients were entered; synthetic data only, no recurrence information, no event)

1 Radiotherapy (preoperative) then Radiotherapy (postoperative, pelvic)
2 Radiotherapy (preoperative)

6905 MSKCC-????: Liver Metastases; Entry ?? (25 patients were entered; not received)

1 5-Fluorodeoxyuridine (hepatic artery)
2 5-Fluorodeoxyuridine (portal)

6906 75G MSKCC-7368: Colon Cancer; Entry 1975 ff. (possibly never activated)

1 Control
2 5-Fluoro-Uracil + Methyl-Lomustine
3 Methanol extract of BCG
4 5-Fluoro-Uracil + Methyl-Lomustine + Methanol extract of BCG

6907 81F NCI-D81-024-368 (Yagoda): Phase III; Stage B2, C; Entry 1981 to 1983 (target 108 patients; not received)

1 5-Fluoro-Uracil [dose 1]
2 Methyl-Lomustine + Vincristine + 5-Fluoro-Uracil [dose 2] + Streptozotocin

70 Mid-Atlantic Oncology Program, U.S.A. {Ahlgren, Fryer, Lokich: DEC-1992}

7001 88A1 MAOP-5186: Age > 18; Colon Cancer; Entry 1988 to ? (?20 patients were entered; not received; synthetic data only, no event; inadequate sample, superseded by 7002)

1 Control
2 5-Fluoro-Uracil + Pyroxidine

7002 88A2 MAOP-5186A: Stage C; Colon Cancer; Entry 1990 ff. (? patients were entered; not received)

1 5-Fluoro-Uracil (continuous) + Levamisole
2 5-Fluoro-Uracil (bolus) + Levamisole

71 Milton S. Hershey Medical Center, Philadelphia, U.S.A. {Lipton: 1992}

7101 Aspirin Trial: Stage B2 or C; Entry ?? (? patients were entered; not received)

1 Control
2 Aspirin

7102 Aspirin and Dipyridamole Trial: Stage B or C; Entry ?? (? patients were entered; not received)

1 Control
2 Aspirin + Dipyridamole

72 St Thomas' Hospital, Nashville, U.S.A. {Kaiser: 1992}

7201 Antibiotic Trial: Entry ?? {AB} (? patients were entered; not received)

1 Cefoxitin
2 Erythromycin + Neomycin + Cefazolin

73 National Cancer Institute, U.S.A. {Glatstein, Sugarbaker: 1992}

7301 79D NCI-79-C-11: Entry 1979 to 1982; randomised at second-look surgery after recurrence (? patients were entered; projected accrual 180; stopped early; not received)

1 Radiotherapy (postoperative)
2 Control

7302 79E NCI-79-C-28: Entry 1979 to 1984 (66 patients were entered; some locally recurrent; not received)

1 5-Fluoro-Uracil (iv)
2 5-Fluoro-Uracil (intraperitoneal)

7303 NCI-83-C-57: Liver Metastases; Entry 1983 to 1986 (? patients were entered; not received)

1 Control
2 5-Fluoro-Uracil (perioperative)

7304 83C NCI-83-C-103: Entry 1983 to 1987 (? patients were entered; not received)

1 Control
2 Nutrition (total parenteral)

7305 88B NCI-86-C-40: Age 18-70; Entry 1988 ff. (? patients were entered; not received)

1 Control
2 LAK Cells + rIL-2

74 National Surgical Adjuvant Breast and Bowel Project, U.S.A. {Fisher, Redmond, Rockette: MAY-1995 (THIRD REVISED VERSION, UPDATED TWICE)}

7401 77C NSABP C-01: Colon Cancer; Dukes B and C; Entry NOV-1977 to FEB-1983 (1166 patients were entered)

1 Control
2 5-Fluoro-Uracil + Methyl-Lomustine + Vincristine
3 BCG

7402 77D NSABP R-01: Rectal Cancer; Dukes B and C; Entry DEC-1977 to OCT-1986 (574 patients were entered)

1 Control
2 5-Fluoro-Uracil + Methyl-Lomustine + Vincristine
3 Radiotherapy (postoperative)

7403 84E NSABP C-02: Colon Cancer; Entry MAR-1984 to JUL-1988 (1158 patients were entered)

1 Control
2 (5-Fluoro-Uracil + Heparin) intraportal

7404 87F1 NSABP R-02, Males: Rectal Cancer; Age 18-70; Entry 1987 to 1992 (741 patients were entered into 7404+7405; synthetic data only (409 patients); not received)

1 5-Fluoro-Uracil + Methyl-Lomustine + Vincristine + Radiotherapy postoperative
2 5-Fluoro-Uracil + Methyl-Lomustine + Vincristine
3 5-Fluoro-Uracil + Folinic Acid + Radiotherapy postoperative
4 5-Fluoro-Uracil + Folinic Acid

7405 87F2 NSABP R-02, Females: Rectal Cancer; Age 18-70; Entry 1987 to 1992 (741 patients were entered into 7404+7405; synthetic data only (287 patients); not received)

1 5-Fluoro-Uracil + Folinic Acid + Radiotherapy postoperative
2 5-Fluoro-Uracil + Folinic Acid

7406 87G NSABP C-03: Colon Cancer; Entry 1987 to 1989 (1081 patients were entered; 40 patients missing; synthetic data only; no recurrence information)

1 (5-Fluoro-Uracil + Methyl-Lomustine + Vincristine) x 5
2 (5-Fluoro-Uracil + Folinic Acid) x 6

7407 89B NSABP C-04: Colon Cancer; Entry JUL-1989 to 1990 (2151 patients were entered; synthetic data only, no event; not received)

1 5-Fluoro-Uracil + Folinic Acid
2 5-Fluoro-Uracil + Folinic Acid + Levamisole
3 5-Fluoro-Uracil + Levamisole

7408 93B NSABP R-03: Rectal Cancer; Entry 1993 ff. (75 patients were entered by MAY-1995; not received)

1 (5-Fluoro-Uracil + Folinic Acid) pre- and postoperative
2 (5-Fluoro-Uracil + Folinic Acid) postoperative

7409 91G NSABP C-05: Colon Cancer; Entry 1991 to 1994 (2176 patients were entered; not received)

1 5-Fluoro-Uracil + Folinic Acid + Alpha-Interferon
2 5-Fluoro-Uracil + Folinic Acid

75 Naval Regional Medical Center, San Diego, U.S.A. {Barber: 1992}

7501 76E Antibiotic Trial: Colon Cancer; Entry 1976 to 1977 {AB} (? patients were entered; not received)

1 Control
2 Gentamicin + Clindamycin

76 New England Deaconess Hospital, U.S.A. {Jessup, Lokich, Sears, Steele: JUN-1993}

7601 80E NEDH-D-80001: Entry 1980 to 1987 (22 patients were entered; synthetic data only, with recurrence information)

1 Control
2 5-Fluoro-Uracil

7602 85B1 NEDH-8603: Age < 75; Colon Cancer; Entry 1985 to 1986 (? patients were entered; target accrual 60 in 2y; possibly not activated; not received)

1 Control
2 Gamma 2A Murine Monoclonal Antibody 17-1A

7603 85B2 NEDH-85999: Age 18-75; Colon Cancer; Entry 1986 to 1989 (? patients were entered; target accrual 120 in 3y; possibly not activated; not received)

1 Control
2 Gamma 2A Murine Monoclonal Antibody 17-1A

77 North Central Cancer Treatment Group, U.S.A. {Beart, Ingle, Kahn, Loprinzi, Moertel, O'Connell, O'Fallon, Wieand: MAR-1996}

7701 78D NCCTG-748852: Entry 1978 to 1984; Colon Cancer (all except 21; 'all' pro temp.) (401 patients were entered; synthetic data only, no recurrence information)

1 Control
2 Levamisole
3 Levamisole + 5-Fluoro-Uracil

7702 80F NCCTG-794751: Rectal Cancer; Stage B2, B3, C1, C2, C3; Entry 1980 to 1986 (204 patients were entered; synthetic data only, no recurrence information)

1 Radiotherapy
2 Radiotherapy + Methyl-Lomustine + 5-Fluoro-Uracil

7703 79L NCCTG-794604: Entry DEC-1979 to NOV-1987 (219 patients were entered; 3 additional patients possibly missing)

1 Control
2 5-Fluoro-Uracil (portal)

7704 84F1 NCCTG-INT-0035 / MAYO-844652 (3-Way): Colon Cancer; Stage C; Entry 1984 to 1987 (929 patients were entered; synthetic data only, no information about recurrence)

1 Control
2 Levamisole
3 Levamisole + 5-Fluoro-Uracil x 12

7705 88C1 NCCTG/INT-0089 (NCCTG-874651): Age > 18; Colon Cancer; Stage B, C; Entry MAR-1988 to AUG-1989 (157 patients were entered; synthetic data only (357 patients for 7705-7706 pro temp.; 8 ineligibles missing); not received)

1 Control
2 Interferon-Gamma
3 (5-Fluoro-Uracil + Folinic Acid [low dose]) x 6m

7706 88C2 NCCTG/INT-0089, Part 1: Colon Cancer; Stage B, C; Entry 1988 to 1989 (?342 patients were entered; contained in 7705 pro temp.; not received)

1 Control
2 (5-Fluoro-Uracil + Folinic Acid [low dose]) x 6m
3 (5-Fluoro-Uracil + Folinic Acid [high dose]) x 6m

7707 NCCTG/INT-0089, Part 2: Colon Cancer; Stage B, C; Entry 1989 to 1989 (earlier incorrect interpretation of 7706-7708; not received)

1 5-Fluoro-Uracil + Folinic Acid [low dose]
2 5-Fluoro-Uracil + Folinic Acid [high dose]

7708 88C3 NCCTG/INT-0089, Part 2: Colon Cancer; Stage B, C; Entry 1990 ff. (? patients were entered; not received)

1 (5-Fluoro-Uracil + Levamisole) x 12m
2 (5-Fluoro-Uracil + Folinic Acid [low dose]) x 6m
3 (5-Fluoro-Uracil + Folinic Acid [high dose]) x 6m
4 (5-Fluoro-Uracil + Folinic Acid [low dose] + Levamisole) x 6m

7709 90B NCCTG-894651: Stage B2, C; Entry 1990 to 1992 (? patients were entered; not received)

1 5-Fluoro-Uracil + Levamisole x 6m
2 5-Fluoro-Uracil + Levamisole x 12m
3 (5-Fluoro-Uracil + Levamisole) x 6m + Folinic Acid [low dose]
4 (5-Fluoro-Uracil + Levamisole) x 12m + Folinic Acid [low dose]

7710 __D INT-0114: Rectal Cancer; Dukes B2, C; Entry ?? (? patients were entered; not received)

1 5-Fluoro-Uracil then Radiotherapy + 5-Fluoro-Uracil
2 (5-Fluoro-Uracil + Folinic Acid) then Radiotherapy + 5-Fluoro-Uracil
3 (5-Fluoro-Uracil + Levamisole) then Radiotherapy + 5-Fluoro-Uracil
4 (5-Fluoro-Uracil + Levamisole + Folinic Acid) then Radiotherapy + 5-Fluoro-Uracil

7711 84F2 NCCTG-INT-0035 / MAYO-844652 (2-Way): Stage B; Colon Cancer; Entry 1984 to 1987 (318 patients were entered; synthetic data only, no information about recurrence)

1 Control
2 Levamisole + 5-Fluoro-Uracil x 12

7712 92D INT-0130: Colon Cancer; High Risk of Locoregional Recurrence; Entry OCT-1992 ff. (? patients were entered; not received)

1 5-Fluoro-Uracil + Levamisole
2 5-Fluoro-Uracil + Levamisole + Radiotherapy

7713 68A Antibiotic Trial: Entry 1968 to 1971 {AB} (? patients were entered; not received)

1 Control
2 Neomycin
3 Neomycin + Tetracycline

7714 77B Anastomosis Trial: Entry 1977 ff. (? patients were entered; not received)

1 Hand-Sewn Anastomosis
2 Stapled Anastomosis

7715 86B MAYO-864751 / RTOG-8811 / CLB-8894 / EST-1288 / SWOG-8896: Rectal Cancer; Stage II, III; Age > 18; Entry JUN-1986 to AUG-1990 (688 patients were entered; not received)

1 (Methyl-Lomustine + 5-Fluoro-Uracil) systemic + Radiotherapy + Methyl-Lomustine + 5-Fluoro-Uracil [protracted iv]
2 (Methyl-Lomustine + 5-Fluoro-Uracil) systemic + Radiotherapy + 5-Fluoro-Uracil (bolus during Radiotherapy)
3 5-Fluoro-Uracil systemic + Radiotherapy + 5-Fluoro-Uracil [protracted iv]
4 5-Fluoro-Uracil systemic + Radiotherapy + 5-Fluoro-Uracil (bolus during Radiotherapy)

7716 93C INT-0146 / NCCTG-934653 / EST-7293 / CLB-9396 / SWOG-9411 / RTOG-9415: Colon Cancer; Entry ?1993 ff. (not received)

1 Open Colectomy
2 Laparoscopic-Assisted Colectomy

7717 Allopurinol Mouthwash Trial (Loprinzi): Patients Receiving 5-Fluoro-Uracil ± Folinic Acid; Stomatitis Endpoint; Entry ? (77 patients were entered; not received)

1 Allopurinol
2 Control

78 Piedmont Oncology Association, U.S.A. {Atkins, Case: 1992}

7801 POA-58184: Colon Cancer; Age > 18; Entry 1984 to 1985 (1-2 patients were entered; never activated)

1 Control
2 5-Fluoro-Uracil (intraperitoneal)

79 R.T.O.G., U.S.A. {Russell, Sause: 1992}

7901 73D RTOG 72-03 Preoperative Radiotherapy Trial: ?Rectal Cancer; Entry 1973 to 1975 (54 patients were entered; synthetic data only, no event)

1 Radiotherapy [20Gy preoperative]
2 Radiotherapy [45Gy preoperative]
3 Control

7902 76R1 RTOG 76-04 (4-Way): ?Rectal Cancer; Entry 1976 to 4-NOV-1977 (17 patients were entered; synthetic data only, no event)

1 Control
2 (5-Fluoro-Uracil + Methyl-Lomustine) [iv, every 5wk] x 18m
3 Radiotherapy [45Gy over 5 wk / 51Gy over 6wk postoperative] + (5-Fluoro-Uracil + Methyl-Lomustine) [every 5wk] x 18m
4 Radiotherapy [45Gy over 5 wk / 51Gy over 6wk postoperative]

7903 81P1 RTOG 81-15 / EST 82-83: Stage A, B1; ?Rectal Cancer; Entry NOV-1981 to MAY-1988 (352 patients were entered; no event, 1 patient possibly missing; synthetic data only, no recurrence information; contains 7907 pro temp.)

1 Radiotherapy [5Gy 24h preoperative]
2 Control

7904 83H RTOG 83-18: Colon Cancer; Stage C; Age > 21; Locally Advanced Disease; Entry 1983 to 1985 (18 patients were entered; closed early; synthetic data only, no event)

1 Radiotherapy (postoperative, abdominal)
2 Control

7905 90F RTOG 90-14 (intergroup study, coördinated by CALGB): Rectal Cancer; Entry 1990 ff. (? patients were entered; not received)

1 Unknown
2 Unknown

7906 76R2 RTOG 76-04 (2-Way): Entry 5-NOV-1977 to 1979 (24 patients were entered; synthetic data only, no event)

1 Radiotherapy (postoperative)+ (5-Fluoro-Uracil + Methyl-Lomustine) [iv, every 5wk] x 18m
2 Radiotherapy (postoperative)

7907 81P2 RTOG 81-15 / EST 82-83: Stage B2, B3, C; Entry NOV-1981 to MAY-1988 (352 patients were entered; no event, 1 patient possibly missing; synthetic data only, all in 7903)

1 Radiotherapy [5Gy 24h preoperative] then Radiotherapy [postoperative]
2 Radiotherapy [postoperative]

80 St Vincent's Hospital, New York, U.S.A. {Grossi, Rousselot: 1992}

8001 60C First Chemotherapy Trial: Entry 1960 to 1966 (? patients were entered; not received)

1 Nitrogen Mustard
2 5-Fluoro-Uracil

8002 68B Second Chemotherapy Trial: Entry 1968 to 1975 (522 patients were entered; synthetic data only, no recurrence information)

1 Control
2 5-Fluoro-Uracil

81 Southeastern Cancer Study Group, U.S.A. {Omura, Temple: AUG-1993}

8101 SEG-78-GI-344: Rectal Cancer; Entry 1978 to 1980 (2 patients were entered; not received)

1 Radiotherapy (postoperative)
2 Control

8102 79F SEG-79-GI-345: Colon Cancer; Stage B and C; Entry 1979 to 1981 (28 patients were entered; synthetic data only, no event; 3 ineligibles missing)

1 Control
2 5-Fluoro-Uracil + BCG-Tice

8103 83D SEG-GI-82-351: Colon Cancer; Entry 1983 to 1984 (15 patients were entered; synthetic data only, no event)

1 Control
2 Warfarin

82 Southwest Oncology Group, U.S.A. {Boles, Buroker, Panettiere: OCT-1993 (UPDATED)}

8201 76F SWOG-7618: Rectal Cancer; Entry 1976 to 1978 (35 patients were entered; poor accrual; synthetic data only, no event)

1 Radiotherapy (preoperative)
2 Radiotherapy (preoperative) + (5-Fluoro-Uracil [1g/m² iv, d1-4,28-31] + Mitomycin-C [10mg/m², d1]) (5wk preoperatively)

8202 75F1 SWOG-7510, 2-way: Colon Cancer; Entry MAR-1975 to JUL-1977 (309 patients were entered)

1 5-Fluoro-Uracil + Methyl-Lomustine
2 5-Fluoro-Uracil + Methyl-Lomustine + BCG

8203 75F2 SWOG-7510, 3-way: Colon Cancer; Entry JUL-1977 to AUG-1980 (317 patients were entered)

1 5-Fluoro-Uracil + Methyl-Lomustine
2 5-Fluoro-Uracil + Methyl-Lomustine + BCG
3 Control

83 Medical College of Virginia Cancer Centre, U.S.A. {Lawrence, Zfass: 1992}

8301 68C Chemotherapy Trial (Lawrence): Entry 1968 to 1975 (203 patients were entered; synthetic data only, no information about recurrence)

1 Control
2 5-Fluoro-Uracil

8302 American Cancer Society Colon Polyp Prevention Trial (Zfass): Entry MAR-1991 ff. (14 patients were entered by 1992; target 2000; not received)

1 Control
2 Dietary Intervention

84 Veterans' Administration Surgical Oncology Group, U.S.A. {Higgins, Page: SEP-1996 (UPDATED)}

8401 58A1 First Study, Part 1 (Curative Surgery Sub-Set): Males; Entry FEB-1958 to JUN-1958 (80 patients were entered; no recurrence information)

1 Control
2 Triethylenephosphoramide [intraperitoneal and iv, high dose] perioperative

8402 58A2 First Study, Part 2 (Curative Surgery Sub-Set): Males; Entry JAN-1959 to JAN-1962 (849 patients were entered; no recurrence information)

1 Control
2 Triethylenephosphoramide [intraperitoneal and iv] perioperative

8404 65B VASOG-19a (Curative Surgery Sub-Set): Males; Entry APR-1965 to FEB-1969 (308 patients were entered; no recurrence information)

1 Control
2 5-Fluoro-Uracil x 5wk

8405 64A VASOG-20: Entry MAR-1964 to JAN-1969 (700 patients were entered; no recurrence information; rectal cancer assumed)

1 Radiotherapy [20-25Gy] preoperative
2 Control

8406 69A VASOG-23 / PIT Trial (Curative Surgery Sub-Set): Males; Entry JAN-1969 to MAY-1974 (522 patients were entered; no recurrence information)

1 Control
2 5-Fluoro-Uracil (iv)

8407 73B VASOG-27A: Colon Cancer; Entry 1973 to 1979 (646 patients were entered; synthetic data only, no information about recurrence)

1 Control
2 5-Fluoro-Uracil + Methyl-Lomustine

8408 73F VASOG-28: Rectal Cancer; Entry AUG-1973 to SEP-1980 (359 patients were entered; no recurrence information; 2 patients possibly missing)

1 Radiotherapy [31·5Gy] preoperative
2 Control

8409 78F VASOG-33: Males; Entry 1978 to 1980 (? patients were entered; not received)

1 5-Fluoro-Uracil x 12wk
2 5-Fluoro-Uracil x 18m
3 5-Fluoro-Uracil + Hydroxyurea

8410 VASOG-27B: Males; Palliative Surgery (microscopic evidence of disease); Entry 1975 to 1980 (210 patients were entered; not received)

1 5-Fluoro-Uracil + Methyl-Lomustine
2 5-Fluoro-Uracil + Methyl-Lomustine + MER

8411 Antibiotic Trial: Colon Cancer; Entry ?? {AB} (? patients were entered; not received)

1 Control
2 Neomycin + Erythromycin

8412 77E1 VASOG-157, 3-Way: Entry 1977 to 1978 {AB} (? patients were entered; not received)

1 Neomycin + Erythromycin
2 Cephalothin
3 Neomycin + Erythromycin + Cephalothin

8413 77E2 VASOG-157, 2-Way: Entry 1978 to 1981 {AB} (? patients were entered; not received)

1 Neomycin + Erythromycin
2 Neomycin + Erythromycin + Cephalothin

8414 62A Chemotherapy Trial (Curative Surgery Sub-Set): Males; Entry JAN-1962 to JAN-1964 (548 patients were entered; no recurrence information)

1 Control
2 5-Fluorodeoxyuridine

8415 VASOG-19b: Males; Histologically-Proven Palliative-Resection Patients; Entry 1965 to 1969 (84 patients were entered; synthetic data only, no information about recurrence)

1 Control
2 5-Fluoro-Uracil indefinite

85 Washington University, U.S.A. {Hill, Wollack: 1992}

8501 62B Antibiotic Trial: Entry 1962 to 1963 {AB} (? patients were entered; not received)

1 Control
2 Chloramphenicol + Methicillin + Benzylpenicillin

8502 78G MO-CO-1: Dukes B and C; Entry 1978 to 1981 (approx. 30 patients were entered; synthetic data only, no recurrence information, no event)

1 Control
2 Vaccinia Oncolysate

86 Western Cancer Study Group, U.S.A. {Chlebowski: AUG-1993 (UPDATED)}

8601 75L Immunotherapy Trial: Dukes B or C; Age < 75; 1:2 Randomisation; Entry JAN-1975 to JAN-1979 (78 patients were entered)

1 Control
2 Levamisole

8602 WDP-67: Stage C; Entry 1975 ff. (not activated)

1 Control
2 Corynebacterium Parvum [5g/m² sc]
3 Corynebacterium Parvum [1·25mg/m² iv]
4 Levamisole [150mg]

87 Yale University, U.S.A. {Kligerman: 1992}

8701 63A Radiotherapy trial: Dukes A, B or C; Entry 1963 ff; 31 patients were entered (synthetic data only, no recurrence information; rectal cancer assumed)

1 Radiotherapy [44-46Gy in 4·5wk, preoperative]
2 Control

88 Policlinico Ferroviario Central, Buenos Aires, Argentina {Araujo: 1992}

8801 82J PFC-GI-1: Colon cancer; Entry 1982 to 1989; ? patients were entered (not received)

1 Doxorubicin + 5-Fluoro-Uracil + Lomustine
2 Doxorubicin + 5-Fluoro-Uracil + Carmustine

89 Flinders University of South Australia, Bedford Park, Australia {Hoffmann: 1992}

8901 Antibiotic trial: Entry ??; ? patients were entered {AB} (not received)

1 Cefoxitin
2 Control

90 Clinical Oncology Society of Australia, Sydney, Australia {Gray, Zalcberg, de Zwart: AUG-1993 (REVISED VERSION (UPDATED))}

9001 88H AUS-C-1 (Phase III Randomised Study of Folinic Acid/5-Fluoro-Uracil as Adjuvant Therapy for Patients with Totally Resected Stage B/C Adenocarcinoma of the Colon): Colon Cancer; Stage B, C; Entry JUN-1988 to MAR-1990 (40 patients were entered)

1 Control
2 5-Fluoro-Uracil + Folinic Acid

9002 78H AUS-CO-2: Entry MAR-1978 to DEC-1981 (301 patients were entered)

1 BCG + Tumour Cells (autologous, neuraminidase-treated)
2 Control

9003 82A COSA-ANZ-BCT-8201: Colon Cancer; Entry JUL-1982 to DEC-1987 (416 patients were entered)

1 5-Fluoro-Uracil intraportal x 7d
2 5-Fluoro-Uracil peripheral systemic x 7d
3 Control

9004 82K COSA-ANZ-BCT-8202 ('Restorative' Sub-Set): Rectal Cancer; Entry NOV-1982 to DEC-1985 (33 patients were entered)

1 Radiotherapy (postoperative, pelvic)
2 Control

9005 92B Phase III Study - Resected Adenocarcinoma (Pilot Study): Colon Cancer; Stage B, C; Entry JUN-1992 ff. (28 patients were entered by NOV-1992; not received: does not exist)

1 5-Fluoro-Uracil + Folinic Acid
2 Control

9006 Phase III Tomudex Trial: Advanced Disease; Entry NOV-1993 ff. (439 patients were entered; not received)

1 ZD1694
2 5-Fluoro-Uracil + Folinic Acid

91 Royal Melbourne Hospital, Australia {Burdon: 1992}

9101 Antibiotic Trial: Entry ?? {AB} (? patients were entered; not received)

1 Control
2 Penicillin [iv]

9102 Antibiotic Trial: Entry ?? {AB} (? patients were entered; not received)

1 Control
2 Gentamicin

9103 Antibiotic Trial: Entry ?? {AB} (? patients were entered; not received)

1 Control
2 Cephalothin

9104 Antibiotic Trial: Entry ?? {AB} (? patients were entered; not received)

1 Control
2 Cephalothin [double dose]

92 Alfred Hospital, Prahan, Australia {McDermott: 1992}

9201 Antibiotic Trial: Entry 1974 to 1977 {AB} (? patients were entered; not received)

1 Control
2 Cephaloridine

9202 79G Antibiotic Trial: Entry 1979 to 1980 {AB} (? patients were entered; not received)

1 Cephazolin
2 Cephazolin + Metronidazole

93 St Vincent's Hospital, Melbourne, Australia {Ryan: 1992}

9301 85C Anaesthesia Trial: Entry 1985 ff. (? patients were entered; not received)

1 Anaesthesia (general: GA)
2 Anaesthesia (regional and general: CRAG)

94 Elisabethinen Hospital, Linz, Austria {Mittermayer: 1992}

9401 81K Antibiotic Trial: Entry 1981 to 1982 {AB} (? patients were entered; not received)

1 Metronidazole + Cefuroxime
2 Metronidazole

95 Vienna University, Austria {Wunderlich: 1993}

9501 78J1 Chemotherapy-Immunotherapy Trial (Part 1): Dukes B, C; Entry 1978 to 1983 (180 patients were entered; synthetic data only, no recurrence information, no event)

1 Control
2 5-Fluoro-Uracil + Mitomycin-C + Cytosine Arabinoside

9502 78J2 Chemotherapy-Immunotherapy Trial (Part 2): Dukes B, C; Entry 1978 to 1983 (180 patients were entered; synthetic data only, no recurrence information, no event)

1 Control
2 Tumour Cells

9503 87R Adjuvant Vaccination Trial: Stage C; Entry JAN-1987 to JUN-1990 (212 patients were entered; not received)

1 Control
2 Vibrio Cholerae Neuraminidase
3 Vibrio Cholerae Neuraminidase + Tumour Cells

96 Catholic University of Campinas, São Paolo, Brazil {Reis Neto: 1992}

9601 78K1 Radiotherapy Trial: Rectal Cancer; Stage A; Entry 1978 to 1980 (7 patients were entered; synthetic data only, no recurrence information)

1 Radiotherapy (preoperative)
2 Control

9602 78K2 Radiotherapy Trial: Rectal Cancer; Stage B; Entry 1978 to 1980 (36 patients were entered; synthetic data only, no recurrence information)

1 Radiotherapy (preoperative)
2 Control

9603 78K3 Radiotherapy Trial: Rectal Cancer; Stage C; Entry 1978 to 1980 (25 patients were entered; synthetic data only, no recurrence information)

1 Radiotherapy (preoperative)
2&nbs